Opioidergic mechanisms underlying the actions of Vitex agnus-castus L.

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 170-177

  Webster, Donna E ^a   He, Ying ^a   Chen, Shao Nong ^a   Pauli, Guido F ^a   Farnsworth, Norman R ^a   Wang, Zaijie Jim ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Botanical; Menopause; Pain; Plant; Premenstrual syndrome

Indexed keywords

APIGENIN; CASTICIN; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; FLAVONOID; ISOKAEMPFERIDE; KAPPA OPIATE RECEPTOR; LUTEOLIN; METHANOL; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; OPIATE RECEPTOR; PETROLEUM ETHER; UNCLASSIFIED DRUG; VITEX AGNUS CASTUS EXTRACT; WATER;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; VITEX AGNUS CASTUS;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DITERPENES; FLAVONOIDS; GLUCOSIDES; HUMANS; MOLECULAR BIOLOGY; PLANT EXTRACTS; PROTEIN BINDING; RECEPTORS, OPIOID; VITEX;

EID: 78549246146     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.013     Document Type: Article

References (34)

1. Hobbs C. Vitex: the women's herb 2003, Healthy Living Publications, Summertown, TN.
2. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 2001, 322(7279):134-137.
3. Halaska M., Raus K., Beles P., Martan A., Paithner K.G. Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo. Ceska Gynekol 1998, 63(5):388-392.
4. Lauritzen C., Reuter H.D., Repges R., Bohnert K.-J., Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus casus: controlled, double-blind study versus pyridoxine. Phytomedicine 1997, 4(3):183-189.
5. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003, 28(Suppl. 3):39-53.
6. Atmaca M., Kumru S., Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003, 18(3):191-195.
7. Sliutz G., Speiser P., Schultz A.M., Spona J., Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res 1993, 25(5):253-255.
8. Jarry H., Leonhardt S., Gorkow C., Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994, 102(6):448-454.
9. Meier B., Berger D., Hoberg E., Sticher O., Schaffner W. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 2000, 7(5):373-381.
10. Wuttke W., Jarry H., Christoffel V., Spengler B., Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine 2003, 10(4):348-357.
11. Webster D.E., Lu J., Chen S.N., Farnsworth N.R., Wang Z.J. Activation of the mu-opiate receptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J Ethnopharmacol 2006, 106(2):216-221.
12. Upton R. Chaste tree fruit, Vitex agnus-castus: standards of analysis, quality control, and therapeutics 2001, American Herbal Pharmacopoeia, Santa Cruz, CA.
13. Jaksch F., Wang M., Roman M. Chaste tree. Handbook of analytical methods for dietary supplements 2005, American Pharmacists Association, Washington, DC, p. 215.
14. Malatynska E., Wang Y., Knapp R.J., Santoro G., Li X., Waite S., et al. Human delta opioid receptor: a stable cell line for functional studies of opioids. Neuroreport 1995, 6(4):613-616.
15. Li J., Li J.G., Chen C., Zhang F., Liu-Chen L.Y. Molecular basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl]benzeneac etamide-induced desensitization and phosphorylation between human and rat kappa-opioid receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 2002, 61(1):73-84.
16. Wang Z., Gardell L.R., Ossipov M.H., Vanderah T.W., Brennan M.B., Hochgeschwender U., et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 2001, 21(5):1779-1786.
17. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22(23):3099-3108.
18. Rhyu M.R., Lu J., Webster D.E., Fabricant D.S., Farnsworth N.R., Wang Z.J. Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J Agric Food Chem 2006, 54(26):9852-9857.
19. Mortola J.F. Premenstrual syndrome-pathophysiologic considerations. N Engl J Med 1998, 338(4):256-257.
20. Chuong C.J., Coulam C.B., Kao P.C., Bergstralh E.J., Go V.L. Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985, 44(6):760-765.
21. Chuong C.J., Hsi B.P. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 1994, 61(6):1039-1044.
22. Tulenheimo A., Laatikainen T., Salminen K. Plasma beta-endorphin immunoreactivity in premenstrual tension. Br J Obstet Gynaecol 1987, 94(1):26-29.
23. Giannini A.J., Martin D.M., Turner C.E. Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 1990, 20(3):279-284.
24. Giannini A.J., Sullivan B., Sarachene J., Loiselle R.H. Clonidine in the treatment of premenstrual syndrome: a subgroup study. J Clin Psychiatry 1988, 49(2):62-63.
25. Webster D.E., Dentali S., Farnsworth N.F., Wang Z.J. Chaste tree and premenstrual syndrome. Natural medications for psychiatric disorders: considering the alternatives 2008, 216-227. Lippincott Williams & Wilkins, Philadelphia. D. Mischoulon, J.E. Rosenbaum (Eds.).
26. Milewicz A., Jedrzejak J. Premenstrual syndrome: from etiology to treatment. Maturitas 2006, 55S:S47-S54.
27. Samochowiec L., Glaesmer R., Samochowiec J. Einfluss von Monchspfeffer auf die Konzentration von beta-Endorphine im Serum weiblicher Ratten. (Summarized in Schmid D, Zulli F. Role of bets-endorphin in the skin. SOFW-Journal 2005;131:1-4.). Aerztezeitschrift fur Naturheilverfahren 1998, 39:213-215.
28. Bruni J.F., Van Vugt D., Marshall S., Meites J. Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci 1977, 21(3):461-466.
29. Kinoshita F., Nakai Y., Katakami H., Imura H. Suppressive effect of dynorphin-(1-13) on luteinizing hormone release in conscious castrated rats. Life Sci 1982, 30(22):1915-1919.
30. Slizgi G.R., Ludens J.H. Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J Pharmacol Exp Ther 1982, 220(3):585-591.
31. Ingkaninan K., von Frijtag Drabbe Kunzel J.K., AP I.J., Verpoorte R. Interference of linoleic acid fraction in some receptor binding assays. J Nat Prod 1999, 62(6):912-914.
32. Balunas M.J., Su B., Landini S., Brueggemeier R.W., Kinghorn A.D. Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod 2006, 69(4):700-703.
33. Hoberg E., Meier B., Sticher O. Quantitative high performance liquid chromatographic analysis of diterpenoids in agni-casti fructus. Planta Med 2000, 66(4):352-355.
34. Katavic P.L., Lamb K., Navarro H., Prisinzano T.E. Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships. J Nat Prod 2007, 70(8):1278-1282.